Beijing Liberation Army 301 Hospital

 The General Hospital of the People's Liberation Army (PLAGH) was founded in 1953 and was formerly the Second Clinical Medical College Affiliated to the China Union Hospital. Over more than half of a century, it has developed itself into a large modern general hospital that has numerous professional talents, all clinical disciplines, state-of-the-art equipments and unique predominance.

apply

The General Hospital of the People's Liberation Army (PLAGH) was founded in 1953 and was formerly the Second Clinical Medical College Affiliated to the China Union Hospital. Over more than half of a century, it has developed itself into a large modern general hospital that has numerous professional talents, all clinical disciplines, state-of-the-art equipments and unique predominance. With medical care, education and research well integrated, the PLAGH has provided health and medical care to the leaders of the CPC Central Committee, the Central Military Commission, the PLA General Headquarters, and to the troops stationed in Beijing. It has also provided diagnosis and treatment for the critically-ill who are transferred from different areas of commands of the PLA. Meanwhile it is open to civilian patients.
  The PLAGH is at the same time the PLA Medical College that was founded in 1958. It is the same institution that has two names and is the only hospital-run education institution in the PLA.

The hospital has more than 40,000 sets of advanced diagnostic and therapeutic equipment such as digital angiography, PET-MR, PET-CT, cyclotron, computed tomography treatment system, hyperbaric oxygen chamber, robotic surgery system, magnetic navigation interventional system, intraoperative CT and intraoperative magnetic resonance. There are 165 clinical and medical departments and 233 nursing units. They have 8 national key disciplines, 1 national key laboratory, 20 provincial and ministerial key laboratories, 33 military medical specialty centers and research institutes. They have formed 13 professional advantages characterized by comprehensive diagnosis and treatment. At the same time, it is the demonstration base of the whole army intensive care and the training base of the Chinese Nursing Society. There are international medical centers and health medical centers to provide high-end preventive health care services. The hospital has an annual outpatient and emergency capacity of more than 490,000 people, accommodating 188,000 people and operating on nearly 90,000 cases.

The hospital has 6 academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering, more than 100 experts with three or more levels of technology, and more than 1,000 professional and technical personnel in Higher Vocational colleges. Among them, 184 doctoral tutors, 293 master tutors and more than 180 serving as the chief and vice-chairmen of the national and military medical professional committees, the hospital has trained more than 4000 high-level clinical medical talents such as master and doctor for the army, more than 10,000 clinical refresher students for military and local hospitals, and tens of thousands of students in specialized courses.
  The PLAGH has 125 clinical, medical and technological departments, 4000 patient beds, and annual volumes of more than 3.8 million outpatient visits, over 110000 admissions and more than 65000 operations.
In this new era, under the leadership of the Party Committee of the PLAGH, aiming at building a first-class modern research-based hospital and following the principle of "being the leading force in the army, a first-class hospital in China and a high-level medical care provider in the world", the medical workers of the hospital have promoted the concept of scientific development and social harmony and written a new chapter about the achievements of the hospital.

Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138

Multiple Myelomabeijing

Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.

more

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma 北京

CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory Multiple Myeloma,however, a subset of patients relapse due to the loss of target in tumor cells.Dual Specificity CD38 and BCMA CAR-T cells can recognize and kill the malignant cells through recognition of CD38 or BCMA.

more